Výsledky vyhledávání - "Elizabeth S. Dunn"

Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis

Autor: Daniel T. Grima, Elizabeth S. Dunn, Lisa M. Bernard, Philip A. McFarlane, David C. Mendelssohn

Publikováno v: PharmacoEconomics. 30:981-989

In many jurisdictions, cost-effectiveness analysis (CEA) plays an important role in determining drug coverage and reimbursement and, therefore, has the potential to impact patient access. Health economic guidelines recommend the inclusion of future c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5df9db5bdb9ae4d963db7f50dcba77c6
https://doi.org/10.2165/11599390-000000000-00000

Zobrazit plný text záznamu

A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom

Autor: Lisa M. Bernard, Daniel T. Grima, Colin A. Hutchison, David C. Mendelssohn, Elizabeth S. Dunn

Publikováno v: Journal of Medical Economics. 16:1-9

There is limited information regarding the cost-effectiveness of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis in the UK. Using a UK National Health Service (NHS) perspective and final results o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a01e8eab045a8e4be2ab28c6ee5b14
https://doi.org/10.3111/13696998.2012.718019

Zobrazit plný text záznamu

Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis

Autor: Daniel T. Grima, Lisa M. Bernard, Elizabeth S. Dunn, David C. Mendelssohn

Publikováno v: Current medical research and opinion. 29(2)

The avoidance of hospitalizations and the maintenance of in-center dialysis sessions in patients receiving dialysis for end-stage renal disease (ESRD) have obvious benefits to patients, dialysis providers and payers. Benefits include better continuit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e57ac1579e6807a337eb8cbb3b728d9
https://pubmed.ncbi.nlm.nih.gov/23216385

Zobrazit plný text záznamu

The Authors’ Reply to van Baal et al.: 'Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.'

Autor: Daniel T. Grima, Lisa M. Bernard, Philip A. McFarlane, Elizabeth S. Dunn, David C. Mendelssohn

Publikováno v: PharmacoEconomics. 31:375-376

In their response to our paper on unrelated medical costs [1], van Baal et al. [2] confirm that our paper identifies inherent problems with many national pharmacoeconomic guidelines regarding the consideration of ‘unrelated’ medical costs. In the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::501452decdf31a59f095e37c113aff41
https://doi.org/10.1007/s40273-013-0046-5

Zobrazit plný text záznamu

48: Impact of Sevelamer on Hospitalization and In-Center Dialysis Utilization: A Modeled Study Based on Dcor

Autor: Daniel T. Grima, Parisa Airia, David C. Mendelssohn, Elizabeth S. Dunn, Lisa M. Bernard

Publikováno v: American Journal of Kidney Diseases. 55:B43

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f58c51d08baae2ea5d48ef6402a786f
https://doi.org/10.1053/j.ajkd.2010.02.055

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání